KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Taxes (2016 - 2025)

CRISPR Therapeutics AG's Current Taxes history spans 11 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Current Taxes rose 146.78% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 146.78%, while the annual FY2025 figure was $1.1 million, 146.78% up from the prior year.
  • Current Taxes for Q4 2025 was $1.1 million at CRISPR Therapeutics AG, down from $3.4 million in the prior quarter.
  • Across five years, Current Taxes topped out at $4.5 million in Q2 2021 and bottomed at $135000.0 in Q4 2022.
  • The 5-year median for Current Taxes is $975500.0 (2024), against an average of $1.7 million.
  • The largest annual shift saw Current Taxes soared 1081.69% in 2021 before it tumbled 95.88% in 2023.
  • A 5-year view of Current Taxes shows it stood at $724000.0 in 2021, then crashed by 81.35% to $135000.0 in 2022, then surged by 224.44% to $438000.0 in 2023, then increased by 2.97% to $451000.0 in 2024, then soared by 146.78% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Current Taxes are $1.1 million (Q4 2025), $3.4 million (Q3 2025), and $715000.0 (Q2 2025).